1[1]Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA, 2000; 283 (24) : 3205 ～3210
2[2]Wang PS, Solomon DH, Mogun H, et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA,2000; 283(24) : 3211～3216
4[4]Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vit ro and in rodent s by st atins. Science, 1999 ; 286 (5446): 1946 ～1949
5[5]Cummings SR, Bauer DC. Do statins prevent both cardiovascular disease and fracture? JAMA,2000; 283(24): 3255～3257
6[6]Cui Q, Wang GJ, Su CC, et al. Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop, 1997 ; 344: 8～19
7[7]Chung YS, Lee MD, Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab,2000; 85(3): 1137～1142
8[8]Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med,2000;132(9): 689～696
9[9]Garnero P, Shin WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab,1994; 79(6):1693～1700
